CRSP - Crispr Therapeutics AG logo

Crispr Therapeutics AG

CRSP

Crispr Therapeutics AG develops gene-based medicines for serious diseases using its CRISPR/Cas9 technology. Its portfolio includes therapies for transfusion-dependent beta-thalassemia, sickle cell disease, and various cancers and autoimmune conditions.

โš•๏ธ Healthcare NASDAQ Listed 2016 $ USD
$1,000 invested 10 years ago โ†’$3,574today

Score Overview

1 Year
Score
Net Growth22.43%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth281.54%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score2.5
Net Growth-219.46%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth-98.53%
Rev Trend33%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-17x
Net Trend40%
Net Income Consistency
Rev Growth159.33%
Rev Trend50%
Revenue Consistency
All Time
Score
Net Growth-17x
Net Trend40%
Net Income Consistency
Rev Growth159.33%
Rev Trend50%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Crispr Therapeutics AG has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. CRSP does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 49.39โ€”
1 Year2025-10-23
$ 67.21-26.51%
5 Years2021-10-22
$ 95.56-48.32%
10 Years2016-10-21
$ 13.82257.38%
All Time2016-10-19
$ 14.09250.53%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 13M-$ 451M$ 2.36B
2025$ 3M-$ 581M$ 1.97B
2024$ 35M-$ 366M$ 1.90B
2023$ 370M-$ 153M$ 1.69B
2022-$ 650M$ 1.81B
2021$ 913M$ 377M$ 2.37B
2020-$ 348M$ 1.69B
2019$ 289M$ 66M$ 943M
2018$ 3M-$ 164M$ 456M
2017$ 40M-$ 68M$ 239M
IPO2016$ 5M-$ 23M$ 315M
CRSP - Crispr Therapeutics AG logo

Crispr Therapeutics AG fundamental performance

Between 2020 and 2025, net income went from -$ 348M to -$ 581M. Revenue increased in 2 of those 5 years; net income in 2.

Between 2016 and 2025, revenue declined from $ 5M to $ 3M and net income went from -$ 23M to -$ 581M. Revenue increased in 50% of the years measured; net income in 40%.

Crispr Therapeutics AG currently holds a 5-year HDB Score of 2.5 out of 10. How the HDB Score is calculated.

Membership

Explore CRSP with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies